Supriyadi Rudi, Rakhima Fauliza, Gondodiputro Rubin Surachno, Darmawan Guntur
Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran - Hasan Sadikin Hospital, Bandung, Indonesia.
Acta Med Indones. 2019 Oct;51(4):318-323.
the prevalence of chronic kidney disease (CKD) and dialysis patients is increasing every year in Indonesia. The impact of CKD and dialysis on patient quality of life (QOL) has been recognized as an important outcome measure in the management of CKD. The Kidney Disease Quality of Life (KDQOL-36) has been validated and is widely used as a measure of QOL for CKD and dialysis patients in many countries, but not in Indonesia. The aim of this study is to determine the reliabity and validity of the Indonesian version of KDQOL-36 on hemodialysis patients in Indonesia.
the KDQOL-36 was translated into Indonesian language by a certified translator and then it was back-translated into English. The translated questionnaire was further reviewed by an expert panel. The final questionnaire was administered to hemodialysis patients in Hemodialysis Unit at Hasan Sadikin General Hospital. Validity was measured using Pearson's correlation between the kidney disease-targeted scores, generic dimensions (SF-12) scores and each scale score in KDQOL-36. The internal consistensy was assessed using Cronbach's Alpha and reliability was examined using test-retest.
out of 103 patients, we found that most subjects were male (52.4%) with median age of 51 (22-75) years. The duration of hemodialysis was 3.4 (SD 2.1) years. The validity test showed a significant correlation (p<0.001) on kidney disease-targeted total score, SF-12 and each score of the scale within it. All of the KDQOL-36 scales showed good test-retest reliability. Internal consistency reliability values were acceptable, with Cronbach's Alpha >0,7 for all scales.
the Indonesian version of the KDQOL-36 questionnaire is valid and reliable for evaluating QOL in reguler hemodialysis patients.
印度尼西亚慢性肾脏病(CKD)和透析患者的患病率逐年上升。CKD和透析对患者生活质量(QOL)的影响已被视为CKD管理中的一项重要结局指标。肾脏病生活质量量表(KDQOL - 36)已得到验证,并在许多国家广泛用作CKD和透析患者QOL的衡量指标,但在印度尼西亚尚未如此。本研究的目的是确定印度尼西亚版KDQOL - 36对印度尼西亚血液透析患者的信度和效度。
KDQOL - 36由一名认证翻译人员翻译成印度尼西亚语,然后再回译成英语。翻译后的问卷由一个专家小组进一步审查。最终问卷被发放给哈山·萨迪金综合医院血液透析科的血液透析患者。使用KDQOL - 36中针对肾脏病的得分、一般维度(SF - 12)得分与各量表得分之间的Pearson相关性来衡量效度。使用Cronbach's Alpha评估内部一致性,并使用重测法检验信度。
在103名患者中,我们发现大多数受试者为男性(52.4%),中位年龄为51岁(22 - 75岁)。血液透析时长为3.4年(标准差2.1年)。效度测试显示,针对肾脏病的总分、SF - 12以及其中各量表得分之间存在显著相关性(p<0.001)。所有KDQOL - 36量表均显示出良好的重测信度。内部一致性信度值是可接受的,所有量表的Cronbach's Alpha>0.7。
印度尼西亚版KDQOL - 36问卷对于评估常规血液透析患者的QOL是有效且可靠的。